Alnylam Initiates Phase 3 Open Label Extension Study (âAPOLLO-OLEâ) with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)